XyloCor Therapeutics

XyloCor Therapeutics is a biopharmaceutical company focused on developing novel gene therapies to address unmet needs in advanced coronary artery disease. Our lead candidate product, XC001, is in clinical development for patients with refractory angina who have no treatment options. XyloCor also has a secondary product, XC002, in the discovery stage for treating heart tissue damage caused by heart attacks.